Access to anti-retroviral drugs, female in Malawi

Malawi: Access to anti-retroviral drugs, female was 93.0% in 2024. ◆ Volatile

Latest (2024)
93.0%
Change on year
unchanged
World rank
22nd
of 141 countries
All-time high
93.0%
in 2023
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Malawi, 2000–2024

0204060801002000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 1 %2005: 4 %2006: 8 %2007: 13 %2008: 20 %2009: 25 %2010: 30 %2011: 39 %2012: 48 %2013: 55 %2014: 62 %2015: 66 %2016: 74 %2017: 79 %2018: 85 %2019: 86 %2020: 89 %2021: 91 %2022: 92 %2023: 93 %2024: 93 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Malawi stood at 93.0%. That is the highest value across all 25 years on record.

The figure is up 50.0% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Malawi peaked at 93.0% in 2023 and was at its lowest, 0.0%, in 2000.

Malawi ranks 22nd of 141 countries on this measure, in the top quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Malawi, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Malawi, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 1.0%
2005 4.0% +300.0%
2006 8.0% +100.0%
2007 13.0% +62.5%
2008 20.0% +53.8%
2009 25.0% +25.0%
2010 30.0% +20.0%
2011 39.0% +30.0%
2012 48.0% +23.1%
2013 55.0% +14.6%
2014 62.0% +12.7%
2015 66.0% +6.5%
2016 74.0% +12.1%
2017 79.0% +6.8%
2018 85.0% +7.6%
2019 86.0% +1.2%
2020 89.0% +3.5%
2021 91.0% +2.2%
2022 92.0% +1.1%
2023 93.0% +1.1%
2024 93.0% +0.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 7.1% 0.0% 25.0% 10
2010s 62.4% 30.0% 86.0% 10
2020s 91.6% 89.0% 93.0% 5

Countries ranked near Malawi

  1. 19 Cameroon 95.0% compare
  2. 19 Sierra Leone 95.0% compare
  3. 19 Tajikistan 95.0% compare
  4. 22 France 93.0% compare
  5. 22 Morocco 93.0% compare
  6. 25 Denmark 91.0% compare
  7. 25 Saudi Arabia 91.0% compare

See the full ranking of 160 places →

More gender data for Malawi

All data for Malawi →

Frequently asked questions

What is access to anti-retroviral drugs, female in Malawi?
Access to anti-retroviral drugs, female in Malawi was 93.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Malawi?
The highest recorded value was 93.0% in 2023.
What is the lowest access to anti-retroviral drugs, female recorded in Malawi?
The lowest recorded value was 0.0% in 2000.
How does Malawi rank for access to anti-retroviral drugs, female?
Malawi ranks 22nd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Malawi?
Over the last ten years it is up 50.0%. The long-run trend across the full record is volatile.
Where does this Malawi data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Malawi. Statizoid, drawing on UNAIDS estimates. Retrieved 07 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/malawi/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/malawi/">Access to anti-retroviral drugs, female in Malawi</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.